Repligen Corporation

Repligen is a bioprocessing-focused life sciences company with a 40-year history of expertise and innovation in the production of biologic drugs, especially monoclonal antibodies. Headquartered in Waltham, Massachusetts, the company operates global manufacturing facilities and markets its products worldwide. Repligen's recent $600.00 million Post-IPO Debt investment on 06 December 2023 reflects strong investor confidence in its capabilities. Despite recent fraudulent activities targeting job applicants, Repligen remains committed to its mission of inspiring advances in bioprocessing through the development and commercialization of high-value products and solutions in the analytics, biotechnology, consumer goods, health care, manufacturing, and pharmaceutical industries. Investors should note that all legitimate communications from Repligen will come from individuals with email addresses ending in @repligen.com and may contact [email protected] to verify communication authenticity. With its strategic positioning in the bioprocessing market, Repligen presents a compelling opportunity for venture capital investment in the life sciences sector.